NEW YORK (GenomeWeb) – Cancer drug developer Celsion last week announced that it had closed its acquisition of nucleic acid drug developer Egen, giving it a portfolio of clinical and preclinical drug candidates, as well as a lung-specific delivery technology for RNAi and microRNA therapeutics.

Under the deal, a wholly owned subsidiary of Celsion acquired the assets of Egen in exchange for $10.6 million in stock and $3.4 million in cash.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.